257 related articles for article (PubMed ID: 27526189)
1. Comparative effectiveness of ramosetron for preventing chemotherapy-induced nausea and vomiting: a systematic review and meta-analysis.
Song HJ; Seo HJ; Son H
Eur J Clin Pharmacol; 2016 Nov; 72(11):1289-1301. PubMed ID: 27526189
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of the combination neurokinin-1 receptor antagonist, palonosetron, and dexamethasone compared to others for the prophylaxis of chemotherapy-induced nausea and vomiting: a systematic review and meta-analysis of randomized controlled trials.
Chow R; Tsao M; Chiu L; Popovic M; Milakovic M; Lam H; DeAngelis C
Ann Palliat Med; 2018 Apr; 7(2):221-233. PubMed ID: 29764184
[TBL] [Abstract][Full Text] [Related]
3. Should palonosetron be a preferred 5-HT
Chow R; Warr DG; Navari RM; Tsao M; Popovic M; Chiu L; Milakovic M; Lam H; DeAngelis C
Support Care Cancer; 2018 Aug; 26(8):2519-2549. PubMed ID: 29796708
[TBL] [Abstract][Full Text] [Related]
4. Pinellia ternata-containing traditional Chinese medicine combined with 5-HT3RAs for chemotherapy-induced nausea and vomiting: A PRISMA-compliant systematic review and meta-analysis of 22 RCTs.
Zhai X; He Q; Chen M; Yu L; Tong C; Chen Y; Wang J; Fan X; Xie H; Liang Z; Sui X; Zeng L; Wu Q
Phytomedicine; 2023 Jul; 115():154823. PubMed ID: 37099981
[TBL] [Abstract][Full Text] [Related]
5. Ramosetron Versus Ondansetron in Combination With Aprepitant and Dexamethasone for the Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: A Multicenter, Randomized Phase III Trial, KCSG PC10-21.
Kim HJ; Shin SW; Song EK; Lee NR; Kim JS; Ahn JS; Yun HJ; Cho YH; Park KU; Kim SY; Jang JS; Kim SW; Lee HW; Lee SR; Kim YS; Lee SN; Ko YH; Kim HJ; Kang JH
Oncologist; 2015 Dec; 20(12):1440-7. PubMed ID: 26512046
[TBL] [Abstract][Full Text] [Related]
6. Ramosetron, a 5-HT3 receptor antagonist for the control of nausea and vomiting.
Rabasseda X
Drugs Today (Barc); 2002 Feb; 38(2):75-89. PubMed ID: 12532186
[TBL] [Abstract][Full Text] [Related]
7. Efficacy, safety and effectiveness of ondansetron compared to other serotonin-3 receptor antagonists (5-HT3RAs) used to control chemotherapy-induced nausea and vomiting: systematic review and meta-analysis.
Simino GP; Marra LP; Andrade EI; Acúrcio Fde A; Reis IA; De Araújo VE; Cherchiglia ML
Expert Rev Clin Pharmacol; 2016 Sep; 9(9):1183-94. PubMed ID: 27180992
[TBL] [Abstract][Full Text] [Related]
8. A Randomized, Double-Blind Pilot Study of Dose Comparison of Ramosetron to Prevent Chemotherapy-Induced Nausea and Vomiting.
Kim KR; Kang G; Ki MS; Shim HJ; Hwang JE; Bae WK; Chung IJ; Kim JK; Jeong S; Cho SH
Biomed Res Int; 2015; 2015():523601. PubMed ID: 26421292
[TBL] [Abstract][Full Text] [Related]
9. Clinical evaluation of Ramosetron injections in the treatment of cisplatin-induced nausea and vomiting.
Noda K; Ikeda M; Yoshida O; Yano S; Taguchi T; Shimoyama T; Nakashima M
J Int Med Res; 2002; 30(3):211-9. PubMed ID: 12166337
[TBL] [Abstract][Full Text] [Related]
10. Oral cannabinoid for the prophylaxis of chemotherapy-induced nausea and vomiting-a systematic review and meta-analysis.
Chow R; Valdez C; Chow N; Zhang D; Im J; Sodhi E; Lock M
Support Care Cancer; 2020 May; 28(5):2095-2103. PubMed ID: 31916006
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of ramosetron versus ondansetron for postoperative nausea and vomiting after general anesthesia: a meta-analysis of randomized clinical trials.
Gao C; Li B; Xu L; Lv F; Cao G; Wang H; Wang F; Wu G
Drug Des Devel Ther; 2015; 9():2343-50. PubMed ID: 25960637
[TBL] [Abstract][Full Text] [Related]
12. Comparative safety and effectiveness of serotonin receptor antagonists in patients undergoing chemotherapy: a systematic review and network meta-analysis.
Tricco AC; Blondal E; Veroniki AA; Soobiah C; Vafaei A; Ivory J; Strifler L; Cardoso R; Reynen E; Nincic V; Ashoor H; Ho J; Ng C; Johnson C; Lillie E; Antony J; Roberts DJ; Hemmelgarn BR; Straus SE
BMC Med; 2016 Dec; 14(1):216. PubMed ID: 28007031
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of olanzapine for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV) as reported in phase I and II studies: a systematic review.
Chow R; Chiu L; Navari R; Passik S; Chiu N; Popovic M; Lam H; Pasetka M; Chow E; DeAngelis C
Support Care Cancer; 2016 Feb; 24(2):1001-1008. PubMed ID: 26530228
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: A systematic review and meta-analysis.
Yoodee J; Permsuwan U; Nimworapan M
Crit Rev Oncol Hematol; 2017 Apr; 112():113-125. PubMed ID: 28325253
[TBL] [Abstract][Full Text] [Related]
15. A randomized, double-blind, parallel, comparative study to evaluate the efficacy and safety of ramosetron plus dexamethasone injection for the prevention of acute chemotherapy-induced nausea and vomiting.
Ho CL; Su WC; Hsieh RK; Lin ZZ; Chao TY
Jpn J Clin Oncol; 2010 Apr; 40(4):294-301. PubMed ID: 20026457
[TBL] [Abstract][Full Text] [Related]
16. Comparative efficacy and safety of palonosetron with the first 5-HT3 receptor antagonists for the chemotherapy-induced nausea and vomiting: a meta-analysis.
Jin Y; Sun W; Gu D; Yang J; Xu Z; Chen J
Eur J Cancer Care (Engl); 2013 Jan; 22(1):41-50. PubMed ID: 22519361
[TBL] [Abstract][Full Text] [Related]
17. Reviewing current and emerging antiemetics for chemotherapy-induced nausea and vomiting prophylaxis.
Natale JJ
Hosp Pract (1995); 2015; 43(4):226-34. PubMed ID: 26308912
[TBL] [Abstract][Full Text] [Related]
18. Efficacy, tolerability, and safety of cannabinoids for chemotherapy-induced nausea and vomiting--a systematic review of systematic reviews.
Tafelski S; Häuser W; Schäfer M
Schmerz; 2016 Feb; 30(1):14-24. PubMed ID: 26787227
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of Palonosetron vs. Ramosetron for the Prevention of Postoperative Nausea and Vomiting: A Meta-Analysis of Randomized Controlled Trials.
Kim MS; Park JH; Choi YS; Park SH; Shin S
Yonsei Med J; 2017 Jul; 58(4):848-858. PubMed ID: 28541001
[TBL] [Abstract][Full Text] [Related]
20. Phase II trial of ramosetron plus dexamethasone in the prevention of cisplatin-induced nausea and vomiting.
Voravud N; Sriuranpong V
J Med Assoc Thai; 2005 Dec; 88(12):1790-6. PubMed ID: 16518975
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
